Alzheimer's - Dementia, Author Interviews / 20.09.2018

MedicalResearch.com Interview with: [caption id="attachment_44675" align="alignleft" width="128"]Dr Christina Elliott PhD Postdoctoral Researcher Department of Old Age Psychiatry King’s College London Dr. Elliott[/caption] Dr Christina Elliott PhD Postdoctoral Researcher Department of Old Age Psychiatry King’s College London MedicalResearch.com: What is the background for this study? Response: Amyloid-beta (Aβ) and its precursor protein, APP have been long implicated in pathogenesis of Alzheimer’s Disease but how they contribute to disease is not fully understood.  This has been further compounded by numerous failed clinical trials which attempted to target Aβ therapeutically. In Alzheimer’s Disease there is an overproduction of Aβ, which can disrupt how neurons communicate at structures called synapses.  It is thought that progressive synapse loss underpins cognitive impairments commonly seen in Alzheimer Disease patients such as memory loss. Our previous work highlighted a central role of the signalling pathway Wnt signalling in Aβ mediated synapse loss through the induction of dickkopf-1 (Dkk1), a well-known modulator of Wnt signalling. The aim of this study was to further investigate the molecular mechanisms of Aβ mediated synapse loss and explore whether this is connected to the overproduction of Aβ.  By dissecting out the key signalling events involved we hoped this would allow us to identify drugs which could be putative therapeutics for Alzheimer’ Disease.